Abstract

BackgroundThyroid dysfunction is a common complication of chronic hepatitis C (CHC) and its therapy. Takotsubo cardiomyopathy (TCM) is a multifactorial, stress related cardiomyopathy, rarely reported in association with thyrotoxicosis. Simultaneous occurrence of TCM and thyrotoxicosis due to hepatitis C and its treatment has never been reported.Case presentationA 47-year-old woman was admitted for acute chest pain, dyspnea, palpitations and diaphoresis. She had been diagnosed with CHC and had undergone 7 months of IFNα and Ribavirin therapy. At admission electrocardiogram (ECG) showed ST segment elevation, negative T waves and troponin was elevated suggesting ST segment elevation myocardial infarction (STEMI). Echocardiography demonstrated left ventricular apical akinesia and ballooning, with a left ventricular ejection fraction (LVEF) of 35%. Contrast angiography showed normal epicardial coronaries, yet a ventriculogram revealed left ventricular apical ballooning, consistent with TCM. Cardiac MRI showed left ventricle apical ballooning and no late enhancement suggesting the absence of any edema, scar or fibrosis in the left myocardium. She was diagnosed with non-autoimmune destructive thyroiditis: TSH=0.001 mU/L, free T4=2.41 ng/dl, total T3=199 ng/dl and negative thyroid antibodies. The thyroid ultrasonography showed a diffuse small goiter, no nodules and normal vascularization of the parenchyma. Following supportive treatment she experienced a complete recovery after a few weeks and she successfully completed her antiviral treatment, with no thyroid or cardiovascular dysfunction ever since. In patients treated with IFNα for CHC, the prevalence of thyroid dysfunction varies between 2.5–45.3% of cases. TCM is a stress related cardiomyopathy characterized by elevated cardiac enzymes, normal coronary angiography and an acute, transient, left ventricular apical dysfunction that mimics myocardial infarction. Most of the patients survive the initial acute event, typically recover normal ventricular function within one to four weeks and have a favorable outcome, as was the case with our patient. Thyrotoxicosis induced stress cardiomyopathy is rare and has been mostly reported in association with Graves’ disease, thyroid storm, thyrotoxicosis factitia or following radioiodine therapy for toxic multinodular goiter.ConclusionRoutine thyroid screening should be done in patients receiving IFN-alpha and Ribavirin for CHC and thyrotoxicosis should be considered as a possible and treatable underlying cause of TCM.

Highlights

  • Thyroid dysfunction is a common complication of chronic hepatitis C (CHC) and its therapy

  • Routine thyroid screening should be done in patients receiving IFN-alpha and Ribavirin for CHC and thyrotoxicosis should be considered as a possible and treatable underlying cause of Takotsubo cardiomyopathy (TCM)

  • Thyroid dysfunction is more prevalent in patients treated with IFN-α and Ribavirin combination therapy (12.1%) than in patients treated with IFN-α alone (6.6%) [5]

Read more

Summary

Conclusion

As previously suggested [4], we believe that TSH and thyroid antibody levels should be measured in all hepatitis C patients prior to starting IFNα therapy and TSH levels should be monitored every three months until completion of IFNα course. In hepatitis C patients treated with IFNα, multidisciplinary teams (gastroenterologist, endocrinologist, cardiologist) should be aware that thyrotoxicosis could be a possible and treatable underlying cause of TCM. Consent Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. Authors’ contributions CSM led the composition of this case report, acquisition of data and drafted the manuscript. CGB and AES participated in the endocrinological management and reviewed the manuscript. LNI participated in the cardiological treatment and performed echocardiography interpretation. DRD and CSM continue clinical follow up of the patient to date. DRD and SVF critically reviewed the manuscript. All authors read and approved the manuscript

Background
Discussion
35. Bahouth SW
Findings
37. Dillmann WH
41. Cakir M
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.